INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. SI 39754-0674A 10

SERIAL NO. 10/000,439

PTO-1449

APPLICANT: Andrew Saxon, et al.
FILING DATE: 10/24/2001

GROUP: 1644

	т	U.S.	PATENT DOCUMENTS	,		
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DAT
/PH/	*5,141,648	08/25/1992	Hylarides, et al.	210	635	
	*5,358,710	10/25/1994	Sehon, et al.	424	178.1	
	*5,512,283	04/30/1996	Byers, et al.	124	171.1	
	*5,558,869	09/24/1996	Burks, Jr., et al.	424	276.1	
	*5,560,915	10/01/1996	Patterson, et al.	424	275.1	
	*5,637,454	06/10/1997	John B. Harley	435	. 005	
	*5,645,820	07/08/1997	David Allen Halfer, et al.	424	041	
	*5,672,683	09/30/1997	Friden, et al.	530	350	
	*5,736,507	05/07/1998	Anna Maria Boots, et al.	514	002	
	*5,843,449	12/01/1998	Anna Maria Boots, et al.	424	185.1	
	*5,869,093	02/09/1999	Howard L. Weiner, et al.	424	451	
	*5,880,103	03/09/1999	Urban, et al.	514	44	
	*5,977,307	11/05/1999	Friden, et al.	530	350	
	*6,103,697	08/15/2000	Bergstrand, et al.	514	14	
	*6,214,974	04/10/2001	Rosenblum, et al.	530	39 .9	
	*6,228,373	05/08/2001	Bergstrand, et al.	424	278 1	
	*6,228,374	05/08/2001	Bergstrand, et al.	424	278.	
	*6,287,792	09/11/2001	Pardridge, et al.	435	7.5	
V	*6,372,250	04/16/2002	Pardridge, et al.	424	450	

		FORE	IGN PAT	ENT DOCUMENT	rs			
EXAMINER'S	PATENT NO.	DA	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIALS							YES	NO
/PH/	*WO 2000/005254	3 February	2000	WIPO	C07K	14/47		×
/PH/	*WO 1999/067293	29 December	er 1999	WIPO		16/46		×
								\boxtimes
								×
								×
								×
								\boxtimes
								\boxtimes
								\boxtimes
								\boxtimes
								×
								⊠
								×
								×
	OTHER DOC	UMENTS (In	cluding A	uthor, Title, Date,	Pertinent Pag	es, Etc.)		
/PH/	*Alvarez-Fernandez, Marcia, et al., "Inhibition of Mammalian Legumain by Some Cystatins Is Due to a Novel Second Reactive Site", The Journal of Biological Chemistry, Vol. 274, No. 27, Issue of July 2, pp. 19195-19203, 1999							
EXAMINER	/Phuong Huynh/ DATE CONSIDERED 09/13/2007							

SHEET 2 OF 8 SERIAL NO. ATTY, DOCKET NO. INFORMATION DISCLOSURE 39754-0674A STATEMENT 10/000 439 APPLICANT: Andrew Saxon, et al. PTO-1449 FILING DATE: 10/24/2001 GROUP: 1644 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) /PH/ *American Autoimmune Related Diseases Association, Questions and Answers, pp. 1-4, 07/26/2001 (http://www.aarda.org/questions and answers.html) *Resources for Health Professionals: Anaphylaxis, pp. 1-10, 09/18/2001 (http://www.worldallergy.org/professional/allergy_update/anap.../anaphylaxissynopsis.shtm) *ANSARI, AA, et al., "Epitope Mapping of the Branched Chain Alpha-Ketoacid Dehydrogenase Dihydrolipoyl Transacylase (BCKD-E2) Protein that Reacts with Sera from Patients with Idiopathic Dilated Cardiomyopathy", (abstract), J Immunol, 153(10):4754-65, 15 November 1994 *AroTec Diagnostics Limited - B2-Glycoprotein 1 (human), pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5002.htm) *AroTec Diagnostics Limited - Myeloperoxidase (pANCA) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5009.htm) *AroTec Diagnostics Limited - Proteinase 3 (cANCA) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5008.htm) *AroTec Diagnostics Limited - La (SSB) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5010.htm) *AroTec Diagnostics Limited - Ro (SSA) Antigen, pp. 1-3, July 11, 2001 (http://webnz.com/arotec/masa5011.htm) *AroTec Diagnostics Limited - Sm Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5007.htm) *AroTec Diagnostics Limited - RNP/Sm Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5006.htm) *AroTec Diagnostics Limited - Scl-70 Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5001.htm) *AroTec Diagnostics Limited - Parietal Cell Antigen (H/K-ATPase), pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5004.htm) *AroTec Diagnostics Limited - Jo-1 Antigen, pp. 1-2, 07/11/2001 (http://webnz.com/arotec/masa5005.htm)

DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*"Autoantigen Sequences", pp. 1-3, 07/11/2001 (http://129.206.51.31/mb/ana base.html) *"Autoimmune Disease: Rapid Progress in our Understanding of Immune Function Promises More Effective Treatments for Autoimmune Disorders", Nature Biotechnology, Vol. 18, pp. IT7-

*BARKER RN, et al., "Red Blood Cell Glycophorins as B and T-cell Antigents in Canine Autoimmune Haemolytic Anaemia", (abstract) Vet Immunol Immunopathol, 47(3-4):225-38,

09/13/2007

FXAMINER

IT9, Supplement 2000

August 1995 /Phuona Huynh/

			SHEET 3 OF 8		
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.		
		39754-0674A	10/000,439		
		APPLICANT: Andrew Saxon, et al.			
		FILING DATE: 10/24/2001	GROUP: 1644		
	OTHER DOCUMENTS	Including Author, Title, Date, Pertin	ent Pages, Etc.)		
/PH/	*"alphaß-Crystallin In Mul (http://www.albany.net/~tjo	tiple Sclerosis", J. Immunol, Vol. 129-135, pp. 1-5, July 20, 2001 c/crystalline.html)			
	*BAJRAMOVIC, JJ, et al., "Presentation of αB-Crystallin to T Cells in Active Multiple Sclerosis Lesions: An Early Event Following Inflammatory Demyelination", The American Association of Immunologists, Vol 164, pp. 4359-4366, 2000				
		re on "Autoimmune Disease", The 7.1.60/Lectures/PB/Autoimmune.ht			
	*BONFA, E., et al., "Frequency and Epitope Recognition of Anti-Ribosome P Antibodies from Humans with Systemic Lupus Erythematosus and MRL/lpr Mice are Similar", (abstract), J Immunol; 140(1):3434-3437, 15 May 1998				
	*BRIDGES, SL, Jr., et al., "T-Cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis", Emerging Therapies for Rheumatoid Arthritis, Vol. 24, pp. 641-650, 1998				
	*CAMBIER, JC, "Commentary: Inhibitory receptors abound?", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 5993-5995, 1997				
	*CHAPMAN, MARTIN D., et al., "Recombinant Allergens for Diagnosis and Therapy of Allergic Disease", J Allergy Clin Immunol, pp. 409-418, 2000				
	*CRITCHFIELD, JM, et al., "T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis", Science Feb 25; 263(5150):1139-43, 1994 (abstract)				
	*DE PALMA, R, et al., "Use Of Altered Peptide Ligands To Modulate Immune Responses As A Possible Immunotheraphy For Allergies", Allergy: 55: Suppl 61: 56-59, 2000				
	*DECKER, PATRICE, et al., "Inhibition Of Caspase-3-Mediated Poly (ADP-Ribose) Polymerase (PARP) Apoptotic Cleavage By Human PARP Autoantibodies And Effect On Cells Undergoing Apoptosis," The Journal Of Biological Chemistry, © 2000 by The American Society For Biochemistry And Molecular Biology, Inc., Vol. 275, No. 12, pp. 9043-9046, 24 March 2000				
	*DIETERICH, W., et al., Identification Of Tissue Transglutaminase As The Autoantigen Of Celiac Disease", Nat Med; 3(7):797-801, July 1997 (abstract)				
	*Merck Corp., "Disorders With Type III Hypersensitivity Reactions", The Merck Manual, Sec. 12, Ch. 148, Hypersensitivity Disorders, July 12, 2001				
	*DITZEL, HENRIK J., "Human Antibodies In Cancer And Autoimmune Disease", Immunologic Research; 21(2-3):185-193, 2000				
		"Identification Of A Family Of Hur tients With Scleroderma", (abstract)			
\bigvee	*ELKON, KB, et al., "Lupi 162(2): 459-471, August 1	us Autoantibodies Target Ribosoma 1985	l P Proteins", (abstract) J Exp Med,		
EXAMINER	/Phuong Huynh/	DATE CONSIDERED 09	9/13/2007		

			SHEET 4 OF		
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.		
		39754-0674A	10/000,439		
		APPLICANT: Andrew Saxon, et al.			
		FILING DATE: 10/24/2001	GROUP: 1644		
	OTHER DOCUMENTS (Including Author, Title, Date, Perti	nent Pages, Etc.)		
*FABIEN N., et al., "Autoa		ntibodies Directed Against The Ribosomal P Proteins Are Not Only on Epitope Of The P0, P1 And P2 Proteins", (abstract) J Autoimmune, 19			
	FARIA AM, et al., "Oral Adv Immunol, 73:153-264,	Tolerance: Mechanisms And Thera 1999	peutic Applications", (abstract),		
I	*FRAMPTON, G., et al., "Identification Of Candidate Endothelial Cell Autoantigens In Systemic Lupus Erythematosus Using A Molecular Cloning Strategy: A Role For Ribosomal P Protein PO As An Endothelial Cell Autoantigen", Rheumatology (Oxford), (abstract) 39(10):1114-1120, October 2000				
	*GIOVANNONI, G, et al., "Multiple Sclerosis And Its Treatment", (abstract) J R Coll Physician Lond, 33(4):315-22, Jul-Aug 1999				
* I	*GOLD, DANIEL P., et al., "T-Cell Receptor Peptides As Immunotherapy For Autoimmune Disease", Critical Reviews™ In Immunology, (abstract) 17:507-510, 1997				
N E	*GOLD, DP, "Results Of A Phase I Clinical Trial Of A T-Cell Receptor Vaccine In Patients Wit Multiple Sclerosis. II. Comparative Analysis Of TCR Utilization In CSF T-Cell Populations Before And After Vaccination With A TCRV Beta 6 CDR2 Peptide", (abstract) J Neuroimmuno 76(1-2):29-38, July 1997				
	*GOLD, HA, et al., "The RNA Processing Enzyme RNase MRP Is Identical to the Th RNP And Related to RNase P", (abstract) Science, 245(4924):1377-80, 22 September 1989				
F	*GOTTLIEB, A.B., et al., Anti-CD4 Monoclonal Antibody Treatment of Moderate to Severe Psoriasis Vulgaris: Results of a Pilot, Multicenter, Multiple-Dose, Placebo-Controlled Study", (abstract) J Am Acad Dermatol, 43(4):595-604, October 2000				
		EAS, et al., "Molecular Properties C nistry, Vol. 275, No. 40, pp. 30844	Of The Goodpasture Epitope", The -30848, 6 October 2000		
	*HASELDEN, B.M., et al., "Peptide-Mediated Immune Responses in Specific Immunotherapy", Int Arch Allergy Immunol, 122(4):229-37, 2000				
	*HELLMARK, T., et al., "Characterization of Anti-GBM Antibodies Involved in Goodpasture's Syndrome", (abstract) Kidney Int, 46(3):823-9, September 1994				
Т	*HIRANO, T., et al., "Human Tissue Distribution of TA02, which is Homologous with a New Type of Aspartic Proteinase, Napsin A", (abstract) Jpn J Cancer Res, 91(10):1015-21, October 2000				
	"Histones and Subclasses" http://www.immunovision.	', July 30, 2001, PurifiedAntigens f .com/pg0019.htm)	for Autoimmune Testing,		
		-h h -liid Cd T V	- O-" (-b-tt) It		
	HUGHES, G.R., The Anti 42(8867):341-344, August		s On , (abstract) Lancet,		

			SHEET 5 OF 8		
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.		
		39754-0674A	10/000,439		
		APPLICANT: Andrew Saxon, et al.			
		FILING DATE: 10/24/2001	GROUP: 1644		
	OTHER DOCUMENTS	Including Author, Title, Date, Pertin	ent Pages, Etc.)		
*KARLSSON, F.A., et al., Anemia is the acid-produci Invest, 81(2):475-9, Februa		"Major Parietal Cell Antigen in Aut ng H+, K+adenosine Triphosphatasa ry 1988	oimmune Gastritis with Pernicious e of the Stomach", (Abstract) J Clin		
	*KOZLOWSKI, MAYA, e Interaction with Tyrosine 5 Biology, pp. 2089-2099, V	et al., "SHP-1 Binds and Negatively Modulates the c-Kit Receptor by 169 in the c-Kit Juxtamembrane Domain", Molecular and Cellular ol. 18, No. 4, April 1998			
	*Kronus, "Addison's Disea (http://www.kronus.com/pro	ase", Enzyme Steroid 21-Hydroxylase (21-OH) Antibody, xducts/addisons.html), July 30, 2001			
		, Tissue Transglutaminase (tTg) Autoantibody, oducts/celiac.html), July 30, 2001			
	*Kronus, "Diabetes", (http://	:www.kronus.com/products/diabetes.html), July 30, 2001			
	Kronus, "Neuromuscular" (http://www.kronus.com/pro	[] , Myasthenia Gravis, ducts/neuromuscular.html), July 30, 2001			
	*Kronus, "Thyroid Autoim 2001	nmune", (http://www.kronus.com/products/thyroid-auto.html), July 30,			
	Multiple Sclerosis Lesions	t al., "Visualization of Myelin Basic Protein (MBP) T Cell Epitopes in ss Using a Monoclonal Antibody Specific for the Human ocyte Antigen (HLA)-DR2-MBP 85-99 complex", (abstract), J Exp Med, 2, 2000			
	*LARCHE, MARK, "Spec 2000	'Specific Immunotherapy", British Medical Bulletin, 56 (No. 4): 1019-1036,			
	*MALBEC, ODILE, et al., "The SH2 Domain-containing Inositol 5-Phosphatase SHIP1 Mediate Cell Cycle Arrest by FcyRIIB", JBC Papers in Press., pp. 1-29, May 18, 2001				
	*MCNEIL, H. PATRICK, et al., "Anti-Phospholipid Antibodies are Directed Against a Complex Antigen that Includes a Lipid-Binding Inhibitor of Coagulation: β ₂ -Glycoprotein I (apolipoprotein H)", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 4120-4124, Medical Sciences, June 1990				
	*MIMORI, T., et al., "Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from Patients with Rheumatic Disorders", (abstract) J. Biol. Chem., 261(5):2274-8, February 15, 1986				
	*MISAKI, Y., et al., "The 5 Biol. Chem., 269(6):4240-6	6K Autoantigen is Identical to Hum , 11 February 1994	an Annexin XI", (Abstract) J.		
\bigvee	*Immunovision (Brochure), "Mitochondrial Antigen", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0020.htm), July 30, 2001				
EXAMINER	/Phuong Huynh/	DATE CONSIDERED	09/13/2007		

			SHEET 6 OF	
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.	
		39754-0674A	10/000,439	
		APPLICANT: Andrew Saxon, et al.		
		FILING DATE: 10/24/2001	GROUP: 1644	
	OTHER DOCUMENTS (Including Author, Title, Date, Pertin	ent Pages, Etc.)	
Helical Peripheral Membras		n Early Endosome-Associated Prot ne Protein Flanked by Cysteine "Fir Chem., 270(22):13503-11, June 2 I	ngers" and Contains a Calmodulin-	
*) (b	*Immunovision (Brockere), "nRNP", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pge020.htm)			
In	*NAKAJIMA, ATSUO, et al., "Antigen-Specific T Cell-Mediated Gene Therapy in Collagen-Induced Arthritis", The Journal of Clinical Investigation, Vol. 107, No. 10, pp. 1293-1301 May 2001			
R	*NEWKIRK, MARIANNA M., et al., "Autoimmune Response to U1 Small Nuclear Ribonucleoprotein (U1 snRNP) Associated with Cytomegalovirus Infection", Arthritis Res, 3: 253-258, July 30 2001			
	*NORMAN, PHILIP S., "Therapeutic Potential of Peptides in Allergic Disease", Annals of Allergy, Vol. 71, pp. 330-333, September 1993			
Pa	*OKANO, Y., et al., "Autoantibody to Th Ribonucleoprotein (Nucleolar 7-2 RNA Protein Particle) in Patients with Systemic Sclerosis", Arthritis Rheum, 33(12):1822-8, December 1990, (abstract)			
	*ONO, S.J., "Molecular Genetics of Allergic Diseases", Annu Rev Immunol, 18:347-66, 2000, (abstract)			
	*ROCK, KENNETH L., et al., "Degradation of Cell Proteins and the Generation of MHC Class I. Presented Peptides", Annu. Rev. Immunol., 17:739-79, 1999, (abstract)			
	*CASCIO P, et al., "26Sproteasomes and Immunoproteaseomes Produce Mainly N-Extended Cersions of an Antigenic Peptide", EMBO J, 20(10):2357-2366, May 15, 2001, (abstract)			
	*SERWOLD T, et al., "ER Aminopeptidases Generate a Unique Pool of Peptides for MHC Class I Molecules", Nat. Immunol., July 2001, (abstract)			
Fo	*YEWDELL, JW., et al., "Not Such a Dismal Science: The Economics of Protein Sythesis, Folding, Degradation and Antigen Processing", Trends Cell Biol, 11(7):294-297, July 2001, (abstract)			
C	*FIEBIGER E., et al., "Cytokines Regulate Proteolysis in Major Histocompatibility complex Class II-Dependent Antigen Presentationby Dendritic Cells" J. Exp. Med., 193(8):881-892, April 16, 2001, (abstract)			
	*STOLTZE L, et al., "Two New Proteases in the MHC Class I Processing Pathway", Nat. Immunol., 1(5):413-418, November 2000, (abstract)			
fro		ion of both MHC Class I- and Class valbumin in Murin Phagosomes", F		
AMINER	/Phuong Huynh/	DATE CONSIDERED 09	9/13/2007	

			SHEET 7 OF 8		
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.		
		39754-0674A	10/000,439		
		APPLICANT: Andrew Saxon, et al.			
		FILING DATE: 10/24/2001	GROUP: 1644		
	OTHER DOCUMENTS (Including Author, Title, Date, Pertine	ent Pages, Etc.)		
/PH/ *MANOURY B., et al., "AI II MHC Presentation", Natu		n Asparaginyl Endopeptidase Processes a Microbial Antigen for Classure, 396(6712):625-627, December 17, 1998, (abstract)			
	*Auto Immune, Inc., "Over Technology, July 30, 2001,	view of Oral tolerance Therapy" Re (http://www.autoimmuneinc.com/R	search and Development – OT _D/tech.html)		
	*Immunovision (Brochure), "PCNA Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, (http://www.immunovision.com/pg0061.htm)				
	*PISETSKY, D.S., "The Ro Microbiol Immunol, 247:14	ole of Bacterial DNA in Autoantiboo 3-155, 2000	ly Induction", (abstract) Curr Top		
	*RICKERT, M., et al., "Fusion Proteins for Combined Analysis of Autoantibodies to the 65-kda Isoform of Glutamic Acid Decarboxylase and Islet Antigen-2 in Insulin-Dependent Diabetes Mellitus", Clin Chem, 47(5):926-34, May 2001, (abstract)				
	*Immunovision (Brochure), "Ribosomal P Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, (http://www.immunovision.com/pg0021.htm)				
	*RIDER, LISA G., et al., "Laboratory Evaluation of the Inflammatory Myopathies", Clinical and Diagnostic Laboratory Immunology, Vol. 2, No. 1, p. 1-9, Jan. 1995				
	*RIESE, RICHARD J., et al., "Cathepsin S Activity Regulates Antigen Presentation And Immunity", J. Clin. Invest., Vol. 101, No. 11, 2351-2363, June 1998				
	*Immunovision (Brochure), "Ro/SS-A Antigen", July 30, 2001, (http://www.immunovision.com/pg0013.htm)				
	*NOEL ROSE, et al., The Autoimmune Diseases: Table of Contents, Third Edition, Academic Press 1998				
	*SARIC, TOMO, et al., "MHC Class I-Presented Antigenic Peptides are Degraded in Cytosolic Extracts Primarily by Thimet Oligopeptidase", JBC Papers in Press., Published July 30, 2001				
	*Immunovision (Brochure), "Scl-70 Antigen", Purified Antigens for Autoimmune Testing" (http://www.immunovision.com/pg0017.htm), July 30, 2001				
	*Immunovision (Brochure), "SMITH (sm) Antigen", Purified Antigens for Autoimmune Testing" (http://www.immunovision.com/pg0015.htm), July 30, 2001				
	*SELA, M., "Specific Vaccines Against Autoimmune Diseases", C R Acad Sci III; 322(11):933-8, November 1999, (abstract)				
	*SCHUPPAN, D, et al., "Identification of the Autoantigen of Celiac Disease", Ann N Y Acad Sci., 859:121-6, 17 November 1998, (abstract)				
\checkmark	*STEINMAN, L., "Multiple Sclerosis: a Coordinated Immunological Attack Against Myelin in the Central Nervous System", Cell, 85(3):299-302, May 3 1996, (abstract)				
EXAMINER	/Phuong Huynh/	DATE CONSIDERED	9/13/2007		

			SHEET 8 OF 8		
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.		
		39754-0674A	10/000,439		
		APPLICANT: Andrew Saxon, et al.			
		FILING DATE: 10/24/2001	GROUP: 1644		
0′	THER DOCUMENTS (Including Author, Title, Date, Pertine	ent Pages, Etc.)		
	EINMAN, L., et al., "P (10):2726-31, July 199	Prospects for Specific Immunotherapy in Myasthenia Gravis" FASEB 0, (abstract)			
by a	*STENMARK, HARALD, et al., "Endosomal Localization of the Autoantigen EEA1 is Mediated by a Zinc-Binding FYVE Finger", The Journal of Biological Chemistry, Vol. 271, No. 39, pp. 24048-24054, September 27 1996				
	*Tan EM, "Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology", (abstract), Adv Immunol 1989, 44:93-151				
Glyc	*TARGOFF IN, "Autoantibodies to Aminoacyl-Transfer RNA Synthetases for Isoleucine and Glycine. Two Additional Synthetases are Antigenic in Myositis; J Immunol, 144(5):1737-1743, 1 March 1990, (abstract)				
Wha	*National Institute of Allergy and Infectious Diseases, "Understanding Autoimmune Disease - What are some Examples of Autoimmune Diseases: Rheumatoid Arthritis. (http://www.niaid.nih.gov/publications/autoimmune/examples.htm), July 11, 2001				
Prese	*VAN SECHEL, ARIANNE C., et al., "EBV-Induced Expression and HLA-DR-Restricted Presentation by Human B Cells of aB-Crystallin, a Candidate Autoantigen in Multiple Sclerosis", The American Association of Immunologists, 1999				
	*VAN VENROOIJ, W.J., et al. "Manual of Biological Markers of Disease", Table of Contents, Kluwer Academic Publishers,				
	*VAN VENROOIJ, W.J., Venroij Research Team, Research Topics, General Introduction, "Autoantigens", (abstract), Department of Biochemistry, University of Nijmegen, 11 July 2001				
Aller	*WALLNER, BARBARA P., Short Analytical Review, "Peptide Therapy for Treatment of Allergic Diseases, Clinical Immunology and Immunopathology, Vol. 80, No. 2, August, pp. 105-109, 1996				
	*WARDROP, III, R.M., et al, "Oral Tolerance in the Treatment of Inflammatory Autoimmune Disease, Inflamm. res., 48, pp. 106-119, 1990				
	*YAMAMOTO, A.M., et al., "Anti-Titin Antibodies in Myasthenia Gravis: Tight Association with Thymoma of Nonthymoma Patients", Archives of Neurology, Vol 58, No.6, June 2001				
	*GERMAIN, R.N., "The T Cell Receptor for Antigen: Signaling and Ligand Discrimination", The Journal of Biological Chemistry, Vol. 276, No. 38, pp. 35223-35226, July 2, 2001				
	*Immunovision (Brochure), "La/SS-B", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0014.htm), July 30, 2001				
	*ROSE, N.R., "The Autoimmune Diseases: A Discussion of the Causes and Treatment of Autoimmune Diseases", American Autoimmune Related Diseases Associate, July 26, 2001				
Natu	ZHU, DAOCHENG, "A Chimeric Human-Cat Fusion Protein Blocks Cat-Induced Allergy", Nature Medicine, pp. 1-4, March 2005 (published online at hhtp://www.nature.com/naturemedicine)				
EXAMINER /Phuong Huynh/ DATE CONSIDERED 09/13/2007					